Get Integrated Data for Your Specialty and Interest Aresa
 
Category Select :
Items 121 ~ 140 of 26060, Page 7 of 1303
121. Merck Hosts 2019 Investor Day Outlining Business Momentum, Strong Expected Growth and Focus on Innovative Research and Development - 06/20/2019
 MERCK
122. Medtronic Statement Regarding FDA Circulatory System Devices Panel - 06/20/2019
 Medtronic
  Medical Devices Advisory Committee on paclitaxel-coated therapies in patients with peripheral artery disease (PAD) in the superficial femoropopliteal artery (SFA)
123. AAOS Opposition Statement to Senate HELP Surprise Billing Proposal - 06/20/2019
 American Academy of Orthopaedic Surgeons
124. WHO flags critical funding gap, calls for political parties to join fight against Ebola - 06/19/2019
 WHO
  WHO Director-General briefs Members States on situation in DRC and appeals for funding for the Ebola response
125. AstraZeneca and Merck’s LYNPARZA® (olaparib) Approved in Japan as First-Line Maintenance Therapy in Patients with BRCA-Mutated Advanced Ovarian Cancer - 06/19/2019
 MERCK
  LYNPARZA is the Only PARP Inhibitor Approved in Japan
126. Volleyball: An All-American Sport - 06/19/2019
 American Cancer Society
  Volleyball is fun, demanding, burns lots of calories, and has a low risk of injury. Find out how this uniquely American sport can be part of your active lifestyle.
127. Abbott Hosts Conference Call for Second-Quarter Earnings - 06/19/2019
 Abbott
  ABBOTT PARK, Ill., June 19, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its second-quarter 2019 financial results on Wednesday, July 17, 2019, before the market opens.
128. In the face of slow progress, WHO offers a new tool and sets a target to accelerate action against antimicrobial resistance - 06/18/2019
 WHO
129. 1 in 3 people globally do not have access to safe drinking water ? UNICEF, WHO - 06/18/2019
 WHO
  New report on inequalities in access to water, sanitation and hygiene also reveals more than half of the world does not have access to safe sanitation services.
130. LYNPARZA® (olaparib) Approved in the EU for Use as First-Line Maintenance Therapy in Patients With BRCA-Mutated Advanced Ovarian Cancer - 06/18/2019
 MERCK
  AstraZeneca and Merck’s LYNPARZA Reduced the Risk of Disease Progression or Death by 70% Compared to Placebo Following Response to Platinum-Based Chemotherapy in Phase 3 SOLO-1 Trial / LYNPARZA is the Only PARP Inhibitor Approved in the EU for This Indication
131. FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Monotherapy for Patients with Metastatic Small Cell Lung Cancer (SCLC) with Disease Progression on or After Platinum-Based Chemotherapy and at Least One Other Prior Line of Therapy - 06/18/2019
 MERCK
  Marks First Approval for KEYTRUDA in SCLC
132. Many Cancer Survivors Struggle to Pay For Care - 06/18/2019
 American Cancer Society
  The population of cancer survivors in the US is growing, and many struggle to pay health care costs. A study led by the Centers for Disease Control and Prevention (CDC) finds one-fourth of survivors have problems paying medical bills and one-third worry about them.
133. Abbott Launches First-ever Rapid Point-of-Care HbA1c Test to Aid in the Diagnosis of Diabetes - 06/17/2019
 Abbott
  Afinion™ HbA1c Dx test provides results in three minutes, enabling clinicians to develop informed, individualized care plans during patient consultation / Assay is the first and only rapid point-of-care test cleared by the U.S. Food and Drug Administration (FDA) to aid healthcare professionals in the diagnosis of diabetes
134. FDA Approves Keytruda (Pembrolizumab) for Head and Neck Cancer - 06/14/2019
 American Cancer Society
  The US Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) as a first-line treatment for people with advanced head and neck cancer.
135. Abbott Declares 382ⁿ? Consecutive Quarterly Dividend - 06/14/2019
 Abbott
  ABBOTT PARK, Ill., June 14, 2019 /PRNewswire/ --?The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 32 cents per share.
136. IBM, KPMG, Merck and Walmart to collaborate as part of FDA’s program to evaluate the use of blockchain to protect pharmaceutical product integrity - 06/13/2019
 MERCK
  The FDA pilot program explores innovative and emerging approaches for the tracing and verification of prescription products
137. AMA policy advocates to eliminate non-medical vaccine exemptions - 06/13/2019
 American Medical Association (AMA)
  The AMA adopted policy to actively advocate for legistration, and policies thah incentivize states to eliminte non-medical exemptions from immunizations.
138. All Black Women in the United States May Not Have the Same Level of Risk for Triple-Negative Breast Cancer - 06/13/2019
 American Cancer Society
  We've known for a while that triple-negative breast cancer is more common in black women in the United States, compared to other groups. The news is the prevalence varies significantly depending on where these women were born. American Cancer Society (ACS) researchers found that among black women, those born in the US and Western Africa were diagnosed more often with triple-negative breast cancer than women born in East Africa. The authors published their findings in Cancer, an ACS peer-reviewed journal.
139. New study finds no link between HIV infection and contraceptive methods - 06/13/2019
 WHO
140. MRI Plays A Role in Diagnosis of Cocaine-related Damage to the Heart - 06/13/2019
 Radiological Society of North America
  Cardiac MRI can detect cocaine's effects on the cardiovascular system and help differentiate between acute and chronic conditions. / Cocaine abuse can have devastating effects on the heart.
<<  <  [1]  [2]  [3]  [4]  [5]  [6]  [7[8]  [9]  [10]  >  >>
 


Copyright ~2018 by Medisurf. All Rights Reserved Terms of Service Privacy Email : medalls@medalls.com